• Cyclophilin A Essential for Cyclosporin A Immunosuppression

  2026-04-28

  This study demonstrates that Cyclophilin A is the principal intracellular target mediating Cyclosporin A’s immunosuppressive activity in vivo. Using gene knockout mouse models, the authors show that Cyclosporin A fails to inhibit T-cell activation or prevent transplant rejection in the absence of Cyclophilin A, refining our understanding of its molecular mechanism and guiding future immunosuppressive research.

• Tamoxifen in Translational Research: Rationale, Validation,

  2026-04-27

  Explore Tamoxifen as a selective estrogen receptor modulator redefining breast cancer research, gene knockout workflows, and mechanistic innovation. This article integrates bench evidence (including recent findings on caveolin-1 modulation), competitive context, and strategic guidance for translational scientists—while highlighting APExBIO’s high-purity Tamoxifen (SKU B5965) as a precision research tool.

• Hyperthermia Enhances PARP Inhibitor Sensitivity in BRCA2-Pr

  2026-04-27

  Mei et al. (2025) demonstrate that hyperthermia-induced reduction of BRCA2 protein sensitizes BRCA2-proficient ovarian carcinoma cells to PARP inhibition. This mechanistic insight suggests a clinically actionable strategy to overcome PARP inhibitor resistance in ovarian cancer using combinatorial hyperthermia and PARP inhibitor approaches.

• ALT Cancer Cells Are Not Universally Hypersensitive to ATR I

  2026-04-26

  This study rigorously tests whether cancer cells using the alternative lengthening of telomeres (ALT) pathway are generally hypersensitive to ATR inhibition. Contrary to previous reports, the authors find no universal hypersensitivity among ALT-positive cell lines, highlighting cell line-specific factors in response to ATR inhibitors and refining therapeutic targeting strategies.

• Lypressin Acetate: Cross-Domain Insights in Endocrine and An

  2026-04-25

  Explore the unique pharmacological properties of Lypressin acetate, a lysine vasopressin analog, and discover its advanced applications in both endocrine and emerging antiviral research. This article delivers new mechanistic depth and practical assay guidance you won't find elsewhere.

• Gastrin I: Precision in Gastric Acid Secretion Pathway Resea

  2026-04-24

  Human Gastrin I peptide empowers high-fidelity modeling of gastric acid secretion mechanisms in advanced in vitro and organoid systems. This article details optimized experimental workflows, troubleshooting strategies, and direct links to breakthrough protocols, enabling researchers to leverage Gastrin I for gastrointestinal physiology studies and translational disorder research.

• Protease Inhibitor Cocktail: Plant Protein Stability Redefin

  2026-04-24

  The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) provides robust, broad-spectrum inhibition of endogenous plant proteases, ensuring high protein stability in plant cell and tissue extracts. Its unique composition, optimized for plant systems and free of EDTA, preserves labile protein modifications and enables reliable downstream analyses such as Western blotting. This dossier details its mechanistic rationale, evidence base, workflow integration, and key limitations.

• Viral Targeting of RIPK3: Mechanisms Regulating Necroptosis

  2026-04-23

  Liu et al. reveal that a class of orthopoxvirus proteins acts as viral inducers of degradation (vIRD), promoting ubiquitin-mediated destruction of the necroptosis adaptor RIPK3. This mechanism critically regulates inflammation and pathogenesis during viral infection, providing new insights into host-pathogen interactions and potential experimental workflows.

• Dextrose (D-glucose): Powering Glucose Metabolism Research

  2026-04-23

  Dextrose (D-glucose) is an indispensable research tool for dissecting glucose metabolism and immunometabolic dynamics, especially under conditions of hypoxia and nutrient competition in the tumor microenvironment. Leveraging high-purity D-glucose from APExBIO streamlines experimental reliability and enables translational insights into cancer and immune cell energetics.

• MK 0893: Structural Insights and Translational Protocols in

  2026-04-22

  Explore the advanced structural biology and translational protocols of MK 0893, a potent glucagon receptor antagonist. This article uniquely bridges molecular interaction insights with practical assay implementation for type 2 diabetes research.

• CA-074 Me: Optimizing Cathepsin B Inhibition in Cell Death A

  2026-04-22

  CA-074 Me enables precise dissection of lysosomal cathepsin B’s role in necroptosis, apoptosis, and inflammation, offering robust selectivity and cell permeability. This article details advanced workflows, troubleshooting, and protocol refinements, directly connecting recent mechanistic insights to actionable research strategies.

• Nilotinib (AMN-107): Quantitative Assay Design for BCR-ABL a

  2026-04-21

  Explore how Nilotinib (AMN-107) enables precise quantitative analysis of BCR-ABL and KIT signaling in chronic myeloid leukemia research. This article introduces advanced, evidence-based assay strategies and highlights essential insights from recent methodological breakthroughs.

• High-Dose Bifendate Induces Acute Hypertriglyceridemia in Ro

  2026-04-21

  This study demonstrates that high oral doses of bifendate (DDB), a synthetic derivative of Schisandrin C, sharply increase serum and hepatic triglyceride levels in rabbits and mice. The findings establish a reproducible animal model for acute hypertriglyceridemia and highlight important safety and mechanistic considerations for researchers employing bifendate in hepatic and metabolic studies.

• Dronedarone (Multaq): Applied Workflows for Atrial Fibrillat

  2026-04-20

  Dronedarone (Multaq) from APExBIO stands out for its high purity and workflow-ready solubility, making it ideal for modeling atrial fibrillation and flutter in preclinical research. This guide translates cutting-edge findings into clear protocols, troubleshooting strategies, and evidence-based application tips for advanced cardiac arrhythmia pharmacology.

• Coronavirus Macrodomains Counter PARP-Mediated Antiviral Def

  2026-04-20

  This study reveals that the coronavirus macrodomain is critical for viral evasion of host poly (ADP-ribose) polymerase (PARP)-mediated inhibition and for suppressing interferon responses. By dissecting the molecular interplay between host PARPs and the viral macrodomain, the research provides mechanistic insights with implications for antiviral strategy design.

450 records 20/30 page Previous Next First page 上5页 1617181920 下5页 Last page